The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Recursion Pharmaceuticals (NASDAQ:RXRX) reported updated clinical data for its investigational treatment for familial adenomatous polyposis, or FAP, along with early activity in its solid-tumor ...

Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated ...

Salt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and ...

Recursion Pharmaceuticals, Inc ( (RXRX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Recursion Pharmaceuticals is an AI-enabled drug discovery company, differentiated by its scale and focus on understanding biology. The company has a broad pipeline across various therapeutic areas and ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...

Recursion Pharmaceuticals, Inc. announced that Sanofi has optioned the first development candidate from the two companies?

SALT LAKE CITY, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates ...